Search Results

MC# 21-17
A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

MC# 19-09
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

MC# 20-06
A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors

MC# 22-10
A Phase I First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors